|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Fecal microbiota transplantation as novel therapy in gastroenterology:A systematic review显示文摘AIM:To study the clinical efficacy and safety of Fecal microbiota transplantation(FMT).We systematically reviewed FMT used as clinical therapy.METHODS:We searched MEDLINE,EMBASE,the Cochrane Library and Conference proceedings from inception to July,2013.Treatment effect of FMT was calculated as the percentage of patients who achieved clinical improvement per patient category,on an intention-to-treat basis.RESULTS:We included 45 studies;34 on Clostridium difficile-infection(CDI),7 on inflammatory bowel disease,1 on metabolic syndrome,1 on constipation,1 on pouchitis and 1 on irritable bowel syndrome(IBS).In CDI 90% resolution of diarrhea in 33 case series(n = 867) was reported,and 94% resolution of diarrhea after repeated FMT in a randomized controlled trial(RCT)(n = 16).In ulcerative colitis(UC) remission rates of 0% to 68% were found(n = 106).In Crohn's disease(CD)(n = 6),no benefit was observed.In IBS,70% improvement of symptoms was found(n = 13).100% Reversal of symptoms was observed in constipation(n = 3).In pouchitis,none of the patients(n = 8) achieved remission.One RCT showed significant improvement of insulin sensitivity in metabolic syndrome(n = 10).Serious adverse events were rare.CONCLUSION:FMT is highly effective in CDI,and holds promise in UC.As for CD,chronic constipation,pouchitis and IBS data are too limited to draw conclusions.FMT increases insulin sensitivity in metabolic syndrome. | Noortje G Rossen John K Mac Donald Elisabeth M de Vries Geert R D'Haens Willem M de Vos Erwin G Zoetendal Cyriel Y Ponsioen | 2015 | World Journal of Gastroenterology2015，21，17： | 41 |
| 2 | AGNP精神科治疗药物监测共识指南:2011显示文摘治疗药物监测(Therapeutic drug monitoring,TDM),如通过定量测定血清或血浆药物浓度指导用药剂量优化,已经成为对患者进行精神药物治疗的很有价值的工具。在患者用药依从性难以判断、药物耐受性不佳、治疗剂量下无效以及可能存在药代动力学药物-药物相互作用等情况下,测定药物浓度是很有用的。在精神科,有可能明显获益于TDM的主要患者群体包括儿童、孕妇、老年患者、智力障碍患者、涉及司法的患者、已知或怀疑携带药代动力学相关基因变异的患者,以及合并躯体疾病影响药代动力学的患者。然而,只有将TDM充分整合到临床治疗过程中去,才能发挥其优化药物治疗的潜在优势。为了促进TDM的合理应用,神经精神药理学与药物精神病学协会(Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie,AGNP)的TDM专家组在2004年发表了精神药物治疗药物监测指南。之后,随着知识不断更新,又有许多可能需要进行TDM的新药上市。因此,本次更新将神经精神药物的种类扩展到了128种,并将其TDM必要性划分为从'强烈推荐'到'可能有用'的四个等级。经过大量细致且全面的文献检索与分门别类的汇总整理,将基于循证医学理念的'治疗参考浓度范围'和'剂量相关参考浓度范围'呈现给大家。本共识指南引入了'实验室警戒浓度'的新概念,即实验室需要马上告知治疗医生的药物浓度上限。本共识指南还给出了诸如药物作为细胞色素P450酶的底物和抑制剂的性质,代谢物与母药浓度比值的常见范围,以及与结果解释相关的内容,还提供了何时将TDM与遗传药理学检测相结合的建议。遵循本指南,有助于改善许多患者精神药物治疗的效果,特别是那些存在药代动力学异常的患者。TDM是一门交叉学科,有时针对看起来不一致的数据,需要多学科坦诚地讨论,只有这样,患者才能从这种合作中获益。 | Hiemke C Baumann P Bergemann N Conca A Dietmaier O Egberts K Fric M Gerlach M Greiner C Gründer G Haen E Havemann-Reinecke U Jaquenoud Sirot E Kirchherr H Laux G Lutz UC Messer T Müller MJ Pfuhlmann B Rambeck B Riederer P Schoppek B Stingl J Uhr M Ulrich S Waschgler R Zernig G 李文标(译) 果伟(译) 阮灿军(译) 贺静(译) 汤宜朗(审校) 王传跃(审校) | 2016 | 实用药物与临床2016，19，10： | 37 |
| 3 | Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial显示文摘 | Geert D’Haens Filip Baert Gert van Assche Philip Caenepeel Philippe Vergauwe Hans Tuynman Martine De Vos Sander van Deventer Larry Stitt Allan Donner Severine Vermeire Frank J Van De Mierop Jean-Charles R Coche Janneke van der Woude Thomas Ochsenkühn Ad A | 2008 | The Lancet2008，，9613： | 5 |
| 4 | Infliximab as disease-modifying therapy显示文摘 | D'Haens G R | 2003 | European Journal of Gastroenterology and Hepatology2003，，03： | 1 |
| 5 | The London Posi- tion Statement of the World Congress of Gastroenterology on Biolog- ical Therapy for IBD with the European Crohn's and Colitis Organi- zation: when to start, when to stop, which drug to choose, and how to predict response? 显示文摘 | D'haens GR Panaccione R Higgins PD | 2011 | Am J Gastroenterol2011，106，21： | 1 |
| 6 | Endoscopic and Histological Healing with Infliximab Anti-Tumor Necrosis Factor Antibodies in Crohn's Disease:A European Multicenter Trial显示文摘 | D'HAENS G VAN DEVENTER S VAN HOGEZAND R | 1999 | Gastroenterology1999，116，5： | 1 |
| 7 | Tc-99m HMPAO White Blood Cell Scintigraphy in the Assessment of the Extent and Severity of an Acute Exacerbation of Ulcerative Colitis显示文摘 | BENNINK R PEETERS M D'HAENS G | 2001 | Clin Nucl Med2001，26，2： | 1 |
| 8 | bFGF induces S1P1 receptor expression and functionality in pulmonary artery smooth muscle cells 显示文摘 | Birker-Robaczewska M Studer R Haening B | 2008 | J Cell Biochem2008，105，4： | 1 |
| 9 | The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization:when to start,when to stop,which drug to choose,and how to predict response?显示文摘 | D'Haens GR Panaccione R Higgins PD | 2011 | Am J Gastroenterol2011，106，2： | 1 |
| 10 | The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn Is and Colitis Organization:When to Start, When to Stop, Which Drug to Choose, and How to Predict Response? 显示文摘 | D Haens G R Panaccione R Higgins P D | 2011 | The American journal of gastroenterology2011，106，2： | 1 |
| 11 | Intermediate outcomes of fresh talar osteochondral allografts for treatment of large osteoehon- dral lesions of the talus显示文摘 | Haene R Qamirani E Story RA | 2012 | J Bone Joint Surg A/n2012，94，12： | 1 |
| 12 | Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn' s disease 显示文摘 | D' Haens GR Fedorak R Lemann M | 2009 | Inflamm Bowel Dis2009，15，10： | 1 |
| 13 | Top-down therapy for IBD: rationale and requisite evidence显示文摘 | D HAENS G R | 2010 | Nat Rev Gastroenterol Hepatol2010，7，： | 1 |
| 14 | Duration of recurrent ileitis after ileocolonic resection correlates with presurgical extent of Crohn's disease显示文摘 | D'Haens G R Gasparaitis A E Hanauer S B | 1995 | Gut1995，36，： | 1 |
| 15 | Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease:a European multicenter trial显示文摘 | van Deventer S van Hogezand R | 1999 | Astroenterology1999，116，5： | 1 |
| 16 | Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial显示文摘 | Geert D’Haens Filip Baert Gert van Assche Philip Caenepeel Philippe Vergauwe Hans Tuynman Martine De Vos Sander van Deventer Larry Stitt Allan Donner Severine Vermeire Frank J Van De Mierop Jean-Charles R Coche Janneke van der Woude Thomas Ochsenkühn Ad A | 2008 | The Lancet2008，，9613： | 1 |
| 17 | An iterative method to stabilize a transfer function in the s-and z-domains 显示文摘 | D'haene T Pintelon R Vandersteen G | 2006 | IEEE Transactions on Instrumentation and Measurement2006，55，4： | 1 |
| 18 | Infliximab as disease-modifying therapy显示文摘 | D ′Haens D R | 2003 | Eur J Gastroenterol Hepato2003，15，3： | 1 |
| 19 | Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease显示文摘 | D'Haens GR Fedorak R Lemann M | 2009 | Inflammatory Bowel Diseases2009，15，10： | 1 |
| 20 | Top-down therapy for IBD: rationale and requisite evidence显示文摘 | D'HAENS G R | 2010 | Nat Rev Gastroenterol Hep- atol2010，7，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员